BillionToOne AAQS

Mitä BillionToOne tekee? BillionToOne Inc, a US-based company headquartered in Menlo Park, California, operates within the Health Care sector. The company is scheduled to go public on November 6, 2025, with the ticker symbol BLLN and ISIN US0901681058. BillionToOne Inc is described as a precision diagnostics company focused on innovative molecular counter technology. The company's Quantitative Counting Template (QCT) platform is noted for its ability to count DNA molecules at the single-count level, enabling the detection of risks associated with common and severe genetic diseases. The company's product UNITY is a noninvasive prenatal screening test that analyzes fetal cell-free DNA in a maternal blood sample to screen for cystic fibrosis (CF) and spinal muscular atrophy (SMA). The product is designed to provide diagnostic insights without invasive procedures, leveraging the QCT platform's unique counting capabilities. The company's website is https://www.billiontoone.com/. As of the provided information, no additional details about the company's founding year, key personnel, acquisitions, or specific financial figures are available. The company's focus remains on advancing precision diagnostics through its proprietary technology, targeting genetic disease risk assessment in prenatal care. BillionToOne on yksi Eurpooliin suosituimmista yhtiöistä.